Announcements

• 2013 Announcements
  Warning: implode() [function.implode]: Invalid arguments passed in /var/www/vhosts/clinuvel.com/httpdocs/plugins/xmap/com_k2/com_k2.php on line 191
  
• 2012 Announcements
  • Presentation: Clinical Study Results - US Phase IIa Vitiligo Study CUV102
  • SCENESSE® successful in Phase IIa vitiligo study
  • Appendix 3B & Lapse and Forfeit of Unlisted Conditional Performance Rights, Dec 2012
  • Results of Meeting
  • CEO's AGM Presentation
  • Appendix 4C - quarterly (Q1 2012-13)
  • Notice of Meeting and Proxy Form
  • Observations from Clinuvel’s US vitiligo study published
  • Appendix 3Z - Final Director's Interest Notice
  • Clinuvel confirms date of Annual General Meeting
  • Clinuvel expands its regulatory team while final European regulatory review of SCENESSE® is underway
  • Dr Helmer Agersborg
  • Appendix 4E - Preliminary Financial Report
  • Appendix 4C - quarterly
  • s.708A Notice
  • Appendix 3Y
  • Clinuvel Newsletter July 2012
  • Appendix 3B
  • Clinuvel Placement raises A$6.2 million
  • Appendix 3B and Lapse of Unlisted Conditional Rights
  • Clinuvel commences US Phase III trial of SCENESSE® in rare light and UV disorder
  • Appendix 4C - quarterly
  • Swiss insurers agree to reimburse Clinuvel’s SCENESSE® for rare disease
  • Clinuvel Newsletter April 2012
  • Clinuvel Corporate Update Presentation
  • Appendix 3B
  • Clinuvel, FDA agree in principle to Phase III study with SCENESSE® (afamelanotide)
  • Observations from Clinuvel’s vitiligo and EPP programs being presented at the American Academy of Dermatology
  • Clinuvel Newsletter February 2012
  • Appendix 4D - Half Yearly Report
  • Lapse and Forfeit of Unlisted Share options
  • Clinuvel files European marketing authorisation application for SCENESSE® (afamelanotide)
  • Appendix 4C - quarterly
  • Appendix 3B
  • Response to Price Query
  • Appendix 3B
• 2011 Announcements
  • Letter from the CEO
  • Clinuvel announces positive results from pivotal European Phase III study: endpoints demonstrate clinically relevant treatment effect of afamelanotide
  • Encouraging interim safety results of SCENESSE® in Phase II study in organ transplant recipients (OTRs)
  • Appendix 3B
  • Change of Director's Interest Notice x 4
  • Appendix 3B & Lapse and Forfeit of Unlisted Conditional Performance Rights
  • Clinuvel Newsletter May 2011
  • Results of Meeting
  • CEO's AGM Presentation
  • Clinuvel granted US topical formulation patent
  • Clinuvel demonstrates positive treatment effect of afamelanotide in US Phase II study
  • Media release: Clinuvel announces positive results of first Phase II US study of SCENESSE® in orphan disease erythropoietic protoporphyria (EPP)
  • Amendment to Change of Director's Interest Notice
  • First positive observations from Clinuvel’s US vitiligo trial
  • Appendix 4C - quarterly
  • Clinuvel Newsletter October 2011
  • Notice of Meeting and Proxy Form
  • Clinuvel confirms date of Annual General Meeting
  • Change of Director's Interest Notice
  • Appendix 3B
  • Clinuvel completes pre-clinical program for SCENESSE® (afamelanotide)
  • Appendix 4E - Preliminary Final Report
  • Lapse and Forfeit of Unlisted Share Options & Conditional Performance Rights
  • Letter to Shareholders
  • Appendix 4C - quarterly
  • Clinuvel Corporate Update Presentation
  • Clinuvel records first A$1 million in sales
  • Clinuvel investor update presentation
  • Clinuvel granted Australian formulation patent
  • EMA acknowledges Clinuvel filing afamelanotide in Europe in 2011
  • Clinuvel Relocates Melbourne Office
  • Clinuvel books European Pre-Submission Meeting for SCENESSE® marketing authorisation application (MAA)
  • Appendix 4C - quarterly
  • Letter from the Chairman
  • SCENESSE® (afamelanotide) data to be presented at global porphyria conference
  • Response to an ASX Price Query
  • Appendix 3B & Lapse and Forfeit of Unlisted Conditional Performance Rights
  • FDA allows Clinuvel’s innovative vitiligo trial
  • Clinuvel’s vitiligo program – trial participation
  • FDA allows world first vitiligo drug trial
  • Appendix 4D - Half Yearly Report
  • Initial Director's Interest Notice
  • Clinuvel completes first Phase II US study
  • Clinuvel appoints new Non-Executive Director
  • Appendix 4C
  • Clinuvel hosts 3rd Annual Scientific & Clinical Excellence Meeting (ASCEM III)
  • Letter to shareholders
• 2010 Announcements
  • Clinuvel Share Trading Policy
  • Appendix 3B
  • Amendment to Appendix 3Y
  • Letter from the CEO
  • Appendix 3Y
  • Appendix 3B
  • Clinuvel completes share consolidation
  • TGA grants Orphan Drug Designation for SCENESSE®
  • Approval to Consolidate Share Capital on 10:1 ratio
  • Clinuvel AGM 2010 CEO Presentation
  • Results of Meeting
  • FDA provides positive guidance on Clinuvel's EPP program
  • Appendix 4C
  • Annual Report 2010
  • Notice of Meeting and Proxy Form
  • Clinuvel confirms date of Annual General Meeting
  • Final Director’s Interest Notice
  • Clinuvel Strategic Update
  • Resignation of Non-Executive Director
  • Appendix 3B & Lapse and Forfeit of Unlisted Conditional Performance Rights
  • Appendix 4E Preliminary final report
  • UV-protective drug to be tested for vitiligo
  • Clinuvel to evaluate SCENESSE® as therapy in vitiligo
  • Appendix 3B
  • Appendix 4C - quarterly
  • Webcast transcript: Clinuvel CEO Dr Philippe Wolgen discusses results from the CUV017 trial
  • Successful drug trial results for light intolerant 'shadow jumpers'
  • Clinuvel reports positive results in Phase III porphyria (EPP) clinical trial
  • Novel UV protecting drug delivered by the picogram
  • Clinuvel selects leading US manufacturing partner for SCENESSE®
  • Letter from the CEO
  • US patent to assist drug as potential skin cancer preventative in redheads
  • US patent for alpha-MSH and analogues for use in UV protection
  • Structural changes in preparation for commercial phase
  • Form 605
  • Clinuvel unveils SCENESSE® following European brand approval
  • Italian Medicines Agency (AIFA) provides reimbursement for the treatment of EPP with afamelanotide
  • Italian patients request UV-drug: afamelanotide available for rare sun disorder
  • Lapse of Unlisted Share Options
  • Appendix 3B
  • Corporate Presentation - March 2010
  • Appendix 4C
  • FDA allows US clinical trials of afamelanotide in EPP
  • Lapse of Unlisted Share Options
• 2009 Announcements
  • Clinuvel announces positive Phase III interim results for EPP
  • Media Release: Clinuvel: positive interim Phase III results for unique skin protection drug
  • Open Briefing. Clinuvel. FDA grants IND status
  • FDA allows IND status for Clinuvel's afamelanotide
  • Media Release: FDA allows IND status for Clinuvel's afamelanotide
  • Appendix 4C
  • Clinuvel Corporate Presentation - March 2009
  • Open Briefing. Clinuvel. Revenue Prospects and Strategy
  • Response to an ASX Price Query
  • Appendix 4C
  • May 2009 European Roadshow Presentation
  • EMEA grants Clinuvel new orphan drug designation
  • Lapse and Expiry of Unlisted Share Options
  • Clinuvel announces positive results in Phase II Solar Urticaria study
  • Technical Note: Phase II Solar Urticaria study
  • Appendix 4C
  • Appendix 3Y
  • Clinuvel Afamelanotide Commercialisation Presentation - August 2009
  • Open Briefing. Clinuvel. CEO on afamelanotide commercialisation.
  • Preliminary final report
  • Confirmatory Phase III EPP trial receives approval.
  • CEO Presentation - Rodman and Renshaw Healthcare Conference.
  • Financial Report Year Ended 30 June 2009
  • Conditional Performance Rights Plan
  • Notice of Meeting and Proxy Form
  • Annual Report to shareholders
  • Appendix 3B
  • Appendix 4C
  • Expiry of Unlisted Share Options
  • Open Briefing. Clinuvel. CEO on MAA application to EMEA
  • Clinuvel AGM 2009 Chair and CEO Presentation
  • Results of Meeting
  • Appendix 3Y
  • The European Medicines Agency grants Clinuvel SME status
  • Afamelanotide improved quality of life in cancer patients
  • Media Release: Drug improves quality of life in cancer patients
  • Clinuvel announces PLE Phase III preliminary results
• 2008 Announcements
  • Response to price query
  • Appendix 4C
  • Appendix 3B
  • Appendix 4D Half Yearly Report
  • EMEA grants Clinuvel two orphan drug designations
  • Corporate Briefing on Orphan Medicinal Product Designations
  • Clinuvel Investor Update via teleconference
  • Teleconference transcript of Investor Update held 19 March 2008
  • Update Investor Presentation April 2008
  • Clinuvel's latest pharmacokinetic studies further validate human safety of CUV1647
  • Swissmedic grants Clinuvel Orphan Drug Status for CUV1647
  • Appendix 4C
  • Clinuvel receives approval to begin Phase II Trials in Solar Urticaria
  • Corporate Presentation - FINSIA Lifesciences Showcase
  • World Health Organisation Assigns CUV1647 Generic Name
  • Appendix 3B
  • New Non-Executive Director
  • Appendix 3X - Initial Director's Interest Notice
  • Open Briefing. Clinuvel. Strategy & Clinical Program Update
  • FDA grants Clinuvel orphan-drug designation
  • Appendix 4C
  • Open Briefing. Clinuvel. FDA Orphan Drug Designation Approval
  • Appendix 4E
  • International and Australian investors buyout substantial shareholder
  • Ceasing to be a substantial holder (ASX online)
  • Ceasing to be a substantial holder (ASX online)
  • Becoming a substantial holder (ASX online)
  • Amended Becoming a substantial holder notice (ASX online)
  • Clinuvel commences Phase II trial in Photodynamic Therapy
  • Financial Report Year Ended 30 June 2008
  • Notice of Meeting and Proxy form
  • Appendix 4C
  • 2008 AGM Results of Meeting
  • 2008 CSO AGM Presentation
  • 2008 CEO AGM Presentation
  • Appendix 3B
  • Appendix 3Y
  • Clinuvel lodges IND in US
  • Open Briefing. Clinuvel. Submission of IND Application
• 2007 Announcements
  • Open Briefing Clinuvel CEO on Commercialisation Goals
  • Clinuvel Pharmaceuticals Ltd appoints new Chair
  • Teleconference transcript of Investor Update held 22 November 2007
  • Clinuvel's second regular investor update via teleconference
  • Clinuvel opens Europe office
  • AGM 2007 Results of Meeting
  • Clinuvel AGM Presentation
  • Clinuvel’s drug begins global Phase II skin cancer trials
  • Appendix 4C
  • AGM Notice of Meeting
  • Open Briefing 2 October 2007
  • Financial Report Year Ended 30 June 2007
  • Clinuvel Shareholder Update 19 September 2007 Conference Call
  • Conference Call and Weblink
  • Shareholder Update Repeat Conference Call
  • Shareholder Update
  • Clinuvel initiates regular investor update via teleconference – Updated contact numbers
  • Appendix 3Y
  • Amendment to Appendix 4E
  • Appendix 4E and Preliminary Financial Report
  • Clinuvel Appoints Head of Corporate Development
  • Appendix 3B
  • Appendix 4C
  • Selection of final dosage for development of CUV1647
  • Dr Aston appointed to Goverment Committee
  • Clinuvel relocates Melbourne office
  • Open Briefing®. Clinuvel. Update on Start of Phase III
  • Appendix 3Z - Final Director’s Interest Notice
  • Appendix 3B - Application for Quotation of Additional Securities
  • Phase III trial begins in Erythropoietic Protoporphyria
  • Clinuvel Share Purchase Plan completed
  • Clinuvel board member resigns
  • Phase III trial of CUV1647 begins in Polymorphic Light Eruption
  • Clinuvel Share Purchase Plan
  • Correction to Appendix 3B – Application for Quotation of Additional Securities
  • Appendix 3B - Application for Quotation of Additional Securities
  • Appendix 4C March 2007 Quarterly Report
  • Clinuvel Completes A$26M Private Placement
  • Request for Trading Halt
  • Clinuvel receives approval to begin Phase III trials in EPP
  • Strategic Update to Investors
  • Open Briefing. Clinuvel. CUV1647 Treatment of PDT
  • New Oncology application identified for CUV1647
  • Appendix 4D Half Year Report
  • Open Briefing Clinuvel Phase III PLE Trials
  • Appendix 4C December 2006 Quarterly Report
  • EGM Results
  • Appendix 3B

Clinuvel Section Menu

• About Clinuvel
  • Our Work
  • Mission Statement
  • Vision Statement
  • Company History
  • Contact
• News
  • Webcasts
    • What can vitiligo patients do? – Lee Thomas and Dr Philippe Wolgen, Part 4
    • The future of vitiligo treatment – Lee Thomas and Dr Philippe Wolgen, Part 3
    • Vitiligo trials of SCENESSE® – Lee Thomas and Dr Philippe Wolgen, Part 2
    • SCENESSE® and its use in vitiligo – Lee Thomas and Dr Philippe Wolgen, Part 1
    • Liver transplantation in erythropoietic protoporphyria (EPP)
    • Understanding Vitiligo: Misconception & Myth
    • 'Check up' reports on rare disease EPP and SCENESSE® (afamelanotide)
    • "Focus really pays off in the end"
    • Part Four - The impact of Erythropoietic Protoporphyria (EPP) on life
    • What is my skin type? (the six Fitzpatrick skin types)
    • What is skin? The layers of human skin
    • Quick! I need Sunburn Relief! Remedies and treatment for sunburn.
    • Understanding Vitiligo - Causes & Theories April 2011
    • Part Three - Burning in shadows
    • Increasing Ultraviolet Levels
    • Part Two - "People don't believe what they can't see"
    • Vitiligo and Stem Cells: Narrowband UVB Phototherapy
    • Part one - "Absolute intolerance to light"
    • Vitiligo: a breakthrough therapy
    • אי.פי.פ
    • "Ein Leben im Schatten"
    • Clinuvel CEO discusses positive phase III results
    • A life in the shadow
    • "GMP, setting standards around the world"
    • Clinuvel's manufacturing partner for SCENESSE®
    • „Die Angst vor dem was da noch kommen mag“
    • פרוטופורפיריה אריתרופויטית (אי.פי.פי) היא מחלה גנטית קשה.
    • "נתק את עצמך מהכאב"
    • „Man distanziert sich sozusagen vom Schmerz“
    • "A fantastic outcome for Clinuvel”
    • Light & UV In Australia
    • Final year of filing MAA
    • The evolution of pharmaceutical development
    • Clinuvel's regulatory strategy
    • "the golden age?"
    • "Clinical and regulatory goals"
    • "Where no one has gone before"
    • Clinuvel, improving quality of life
    • "The fear of what lay ahead"
    • "Separate yourself from the pain"
    • Absolute light intolerance: Erythropoietic protoporphyria (EPP)
  • RSS Feeds
  • JAMA features vitiligo study as cover story
  • Clinuvel completes first vitiligo study
  • Clinuvel commences US Phase III trial of SCENESSE® in EPP
  • Clinuvel files European MAA for SCENESSE® (afamelanotide)
  • Updated: Clinuvel announces EU Phase III EPP results
  • Q4 2011 media
  • Clinuvel records first A$1 million in sales
  • Clinuvel Annual General Meeting
  • Phase II US EPP results
• Clinuvel in the Community
  • Scientific Events
  • Sponsorships
  • Clinuvel Online
  • Compassionate Use Program - EPP
  • Join the Team
• Pharmaceutical Development
  • Preclinical Testing
  • Clinical Trials
  • New Molecular Entity
  • Green Pharma
  • Good Manufacturing Practice (GMP)
  • Pharmaceutical Regulation
  • Orphan Drug Designations
• FAQ's

Kids Quicklinks

• Mothers & Children
• Newborn Skin
• Nutrition for Healthy Skin
• Skin During Pregnancy
• Cuts, Bruises & Bites
• Sun Safety
• Sun 'Allergies'

Clinuvel Quicklinks

• Clinuvel
• About Clinuvel
• News
• Clinuvel online
• Clinical Trials
• Pharmaceutical Regulation
• Contact

Investors Quicklinks

• Company Snapshot
• Investors
• Share Price
• Shareholder Services
• Announcements
• Email List
• Contact

SCENESSE Quicklinks

• Vitiligo News
  • First positive observations from Clinuvel’s US vitiligo trial
• EPP News
  • To be a child with EPP
  • Clinuvel announces Phase II US EPP results
• SCENESSE®
• Porphyria (EPP) Program
• Vitiligo Program
• Vitiligo Treatment
• Photodermatoses
• EPP Treatment
• Ongoing Clinical Trials

Skin Quicklinks

• Science of Skin
• Skin Layers
• Melanin
• Common Skin Problems
• Rare Skin Conditions
• UV, Light & Skin

Clinuvel Networks

• Our Networks
• Clinuvel Blog
• Facebook 
• Twitter 
• Youtube 
• Vimeo
• Photoprotection Network 

Footer Menu

• Login/Register
• Site Map
• Disclaimer
• Privacy Policy
• Contact

• Clinuvel

Investors Section Menu

• FAQ
• Our Company
  • Overview
  • People
    • Stanley McLiesh
    • Philippe Wolgen
    • Brenda Shanahan
    • Jack Wood
    • Elie Ishag
    • Dennis Wright
    • Darren Keamy
  • Corporate Governance
  • Business Development
    • Path to Market
    • Intellectual Property
• Investors
  • Share Price
  • Shareholder Services
  • Investing In Clinuvel
  • Financial Overview
• News & Publications
  • Announcements
    • 2011 Announcements
    • 2010 Announcements
    • 2009 Announcements
    • 2008 Announcements
    • 2007 Announcements
    • 2012 Announcements
    • 2013 Announcements
      • s.708A Notice, May 2013
      • Appendix 3B & Lapse and Forfeit of Unlisted Conditional Performance Rights, May 2013
      • Clinuvel Placement completed successfully
      • Suspension from official quotation
      • Request for voluntary suspension
      • Trading Halt
      • Trading Halt Request
      • Appendix 4C - quarterly (Q3 2012-13)
      • Clinuvel Newsletter - April 2013
      • Clinuvel expects EMA outcome in second half of 2013
      • Appendix 3B & Lapse and Forfeit of Unlisted Conditional Performance Rights, March 2013
      • SCENESSE® data to be presented at American Academy of Dermatology, San Gallicano Rare Disease conferences
      • Clinuvel clears EMA manufacturing audit
      • Appendix 4D
      • Appendix 3Y - Feb 2013
      • Appendix 3B, Jan 2013
      • Appendix 4C - quarterly (Q2 2012-13)
      • Corporate Update Presentation
      • Letter from the CEO
  • Newsletter
    • Clinuvel Newsletter - February 2013
    • Clinuvel Newsletter - July 2012
    • Clinuvel Newsletter - April 2012
    • Clinuvel Newsletter - February 2012
    • Clinuvel Newsletter - October 2011
    • Clinuvel Newsletter - May 2011
    • Clinuvel Newsletter - January 2011
    • Clinuvel Newsletter - November 2010
    • Clinuvel Newsletter - August 2010
    • Clinuvel Newsletter - May 2010
    • Clinuvel Newsletter - March 2008
    • Clinuvel Newsletter - July 2008
    • Clinuvel Newsletter - October 2008
    • Clinuvel Newsletter - December 2008
    • Clinuvel Newsletter - February 2009
    • Clinuvel Newsletter - April 2009
    • Clinuvel Newsletter - July 2009
    • Clinuvel Newsletter - June 2007
    • Clinuvel Newsletter - March 2007
    • Clinuvel Newsletter - October 2009
  • Press Coverage
  • Webcasts
  • Annual Reports
    • Annual Report for the year ended 30 June 2012
    • Annual Report for the year ended 30 June 2011
    • Annual Report for the year ended 30 June 2010
    • Annual Report for the year ended 30 June 2000
    • Annual Report for the year ended 30 June 2001
    • Annual Report for the year ended 30 June 2002
    • Annual Report for the year ended 30 June 2003
    • Annual Report for the year ended 30 June 2004
    • Annual Report for the year ended 30 June 2005
    • Annual Report for the year ended 30 June 2006
    • Annual Report for the year ended 30 June 2007
    • Annual Report for the year ended 30 June 2008
    • Annual Report for the year ended 30 June 2009
  • Analyst Reports
    • Nomura update "Funds to be used for further clinical development"
    • Nomura Quick Note: "Delay for European EPP decision"
    • Nomura update "We believe the EMA decision is due in the short-term"
    • Nomura update "Statistically significant results – will progress to a Phase IIb"
    • Nomura Quick Note: "Vitiligo journal article released"
    • Nomura Update "F12 – good progress, expect a F13 EMA decision"
    • Nomura Update "Funds to be used for further clinical development"
    • Nomura Quick Note: "Launches US Phase III trial for EPP treatment"
    • Nomura Quick Note: "Afamelanotide receives approval in Switzerland"
    • Nomura Update "Considerable upside should NSV trials be successful"
    • Nomura Quick Note: "Vitiligo and EPP opportunities progress"
    • Nomura Update "We believe the Vitiligo market is currently underserved"
    • Nomura Quick Note: "MAA review should complete by start 4QCY12"
    • Edison QuickView: Positive in Phase III
    • Nomura Quick Note: "Positive result from pivotal EU Phase III study"
    • Nomura Update "CUV's statistically significant EPP results"
    • Nomura Update "Vitiligo - addressing a large unmet need"
    • Nomura Update "FY11 - looking to enter the Vitiligo market"
    • Nomura Update "1H FY11 – waiting for the sun"
    • NOMURA Analyst Report
    • NOMURA Analyst Report
    • ABN AMRO - update
    • ABN AMRO - update
    • RBS Update
    • Louis Capital - update
    • RRS Capital Strategies Services - update (German only)
    • ABN AMRO - update
    • ABN AMRO - update
    • Intersuisse - update
    • ABN AMRO - update
    • Louis Capital - update
    • ABN AMRO - update
    • RRS Capital Strategies Services - initiation of coverage
    • ABN AMRO - update
    • Intersuisse - update
    • ABN AMRO - update
    • ABN AMRO - initiation of coverage
    • Tolhurst Noall - update
    • Tolhurst Noall - update
    • Tolhurst Noall - update
    • Tolhurst Noall - initiation of coverage
    • ABN AMRO - update
    • RBS Update
    • RBS - "US biogeneric exclusivity extended"
    • RBS Update: Clinuvel Continues to confirm potential
    • RBS - Health Care sector update
    • RBS Update "Interim Phase III results revealed"
    • RBS Update "Analysis of CUV's opportunities"
    • Independent research by Reuters - Buy Recommendation
  • Subscribe to Email Updates
  • Announcements
  • Analyst Reports
  • Annual Reports
  • Newsletter
  • Press Coverage
    • 2011 Press Coverage
    • 2007 Press Coverage
    • 2008 Press Coverage
    • 2009 Press Coverage
• Contact Us

Main Menu

• SCENESSE®
• CUV9900
• Science of Skin
• Mothers & Children
• Investors Area

• Related Sector News
  • 'Me-too' pharma firms will 'disappear' - Roche's Schwan
  • Joint FDA-EMA inspection programme to launch in January 2012
  • Targeted drug side effects add to cancer costs
  • Patent expiries and emerging pharma markets to fuel $100bn generics growth
  • The Drug Hunters Of 2037
  • Germany’s tough reimbursement rules cause drug companies to consider alternative drug trial solutions
• Clinuvel Media Coverage
  • Implant Helps Those With Skin Diseases, and Gives Them a Tan Too
  • EMA acknowledges Clinuvel's novel drug filing in Europe
  • Financial Review - Biotech gets under the skin (Subscription Required)
  • Drug helps the sun to shine for those with an allergy to light
  • Bringing the Online Investor Centre to Life
  • Clinuvel files for marketing approval for SCENESSE in Europe

Mothers & Children Section Menu

• Childrens' Skin
  • Newborns (0 - 18 Months)
    • Common Skin Problems
    • Baby Acne
    • Nappy Rash
    • Nappy (Diaper) Bag Essentials
  • Toddlers (18 months - 4 years)
    • Common Skin Problems
  • Children (5-12 years)
    • Common Skin Problems
  • Teenagers (13-17 years)
    • Common Skin Problems
    • Acne
    • Teenage Skin Issues
  • Nutrition for Healthy Skin
  • Talking to Your Dermatologist
• Mothers' Skin
  • Adult Skin
  • Skin During Pregnancy
  • Common Skin Problems During Pregnancy
  • Postnatal Skin
  • Breastfeeding and Skin
• Cuts, Bruises & Bites
  • Healing Cuts
  • Burns
  • Bruises
  • Bites & Stings
• Sun & Skin
  • Sun Damage & Sunburn
    • Relieving Sunburn
  • Sun Safety
  • Sun 'Allergies' & Photosensitivity
  • Skin Cancer in Children & Teens
  • Sun Protective Clothing

Press Coverage

• 2012 Press Coverage
• 2011 Press Coverage
• 2010 Press Coverage
• 2009 Press Coverage
• 2008 Press Coverage
• 2007 Press Coverage

Scenesse Section Menu

• SCENESSE®
  • Implant Drug Product
  • Clinuvel's Program
    • Ongoing Clinical Trials
  • Clinical Trial Results
    • Phase I
    • Phase II
    • Phase III
  • SCENESSE's Mechanism of Action
    • About Alpha-MSH
    • Melanocortins
    • Biomimicry
    • Photoprotection
    • Repigmentation
  • Research
  • Technology Updates
    • Original Thoughts on UV and Pigmentation
    • Afamelanotide as an Adjunct to Phototherapy
    • Stem Cells and Repigmentation in Vitiligo
• Porphyria (EPP)
  • Completed EPP Trials
  • Ongoing EPP Program
  • Italian Access Scheme 648/96
  • News & Updates
• Vitiligo
  • News & Updates
  • SCENESSE® as a Repigmentation Therapy
  • FAQ
• Photodermatoses & Cancer
  • Skin Cancer in Organ Transplant Patients
  • Polymorphous Light Eruption (PLE)
  • Solar Urticaria (SU)
  • Photodynamic Therapy (PDT) Phototoxicity
• Regulatory Progress
  • Orphan Drug Status

Science of Skin Section Menu

• Downloads
  • Actinic prurigo Information Sheet - 1.0
  • Erythropoietic Protoporphyria Information Sheet - 1.1
  • What is Skin? Information Sheet - 1.0
• Dermatology
  • Skin Layers
  • Melanin
    • Melanin in biology
    • Function skin pigment
  • Skin Care Products
    • Skin Care Ingredients
    • Skin Care Concepts
    • Cleansers
    • Toners
    • Exfoliants
    • Masks
    • Moisturisers
    • Sunscreen
• Skin Conditions
  • Common skin conditions
    • Polymorphous Light Eruption (PLE)
    • Acne
    • Atopic Dermatitis
    • Psoriasis
    • Rosacea
    • Seborrheic Dermatitis (SD)
  • Viral skin conditions
    • Human Papilloma Virus (HPV)
    • Herpes Simplex Virus (HSV)
    • Varicella Zoster Virus (VZV)
  • Pigmentary skin conditions
    • Albinism
    • Vitiligo
  • Rare skin conditions
    • Erythropoietic Protoporphyria (EPP)
    • Porphyria Cutanea Tarda (PCT)
    • Solar Urticaria (SU)
    • Hydroa Vacciniforme (HV)
    • Urticaria Pigmentosa (UP)
    • Actinic Prurigo
    • Xeroderma Pigmentosum (XP)
    • Congenital Erythropoietic Porphyria (CEP)
  • Skin cancer
    • Actinic Keratosis
    • Squamous Cell Carcinoma
    • Basal Cell Carcinoma
    • Melanoma
    • Melanoma
  • Photodynamic Therapy (PDT) and Phototoxicity
  • Common skin conditions
  • Viral skin conditions
  • Pigmentary skin conditions
  • Rare skin conditions
  • Skin cancer
• Skin & Sun
  • UV and Light
  • Light and Skin Interaction
  • Sunburn
    • Sunburn Relief
  • Photoprotection
  • Sunscreen and Pediatric Skin
  • Photoaging
  • Skin cancer
    • Causes of Skin Cancer
    • UV Damage and Carcinogenesis
    • Skin Cancer Prevention
    • Organ Transplant Recipients
  • Tanning
  • Vitamin D
  • Sunbeds and Solariums
  • Increasing Ultraviolet Levels
  • Skin cancer
  • Sunburn
• Contact

Social Networks

• Facebook
• Twitter
• Blog
• Webcasts
• RSS Feeds
• Subscribe to Emails
• Clinuvel's Photoprotection network on YouTube
• Clinuvel Australia on Vimeo